Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 114

1.

Characterization of the canine rostral ventricular-subventricular zone: Morphological, immunohistochemical, ultrastructural, and neurosphere assay studies.

Fernández-Flores F, García-Verdugo JM, Martín-Ibáñez R, Herranz C, Fondevila D, Canals JM, Arús C, Pumarola M.

J Comp Neurol. 2018 Mar 1;526(4):721-741. doi: 10.1002/cne.24365. Epub 2017 Dec 19.

PMID:
29205371
2.

Quality of clinical brain tumor MR spectra judged by humans and machine learning tools.

Kyathanahally SP, Mocioiu V, Pedrosa de Barros N, Slotboom J, Wright AJ, Julià-Sapé M, Arús C, Kreis R.

Magn Reson Med. 2018 May;79(5):2500-2510. doi: 10.1002/mrm.26948. Epub 2017 Oct 10.

PMID:
28994492
3.

Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide.

Ferrer-Font L, Arias-Ramos N, Lope-Piedrafita S, Julià-Sapé M, Pumarola M, Arús C, Candiota AP.

NMR Biomed. 2017 Sep;30(9). doi: 10.1002/nbm.3748. Epub 2017 Jun 1.

PMID:
28570014
4.

Metabolomics of Therapy Response in Preclinical Glioblastoma: A Multi-Slice MRSI-Based Volumetric Analysis for Noninvasive Assessment of Temozolomide Treatment.

Arias-Ramos N, Ferrer-Font L, Lope-Piedrafita S, Mocioiu V, Julià-Sapé M, Pumarola M, Arús C, Candiota AP.

Metabolites. 2017 May 18;7(2). pii: E20. doi: 10.3390/metabo7020020.

5.

Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice.

Ferrer-Font L, Villamañan L, Arias-Ramos N, Vilardell J, Plana M, Ruzzene M, Pinna LA, Itarte E, Arús C, Candiota AP.

Pharmaceuticals (Basel). 2017 Feb 12;10(1). pii: E24. doi: 10.3390/ph10010024.

6.

Brain metabolic pattern analysis using a magnetic resonance spectra classification software in experimental stroke.

Jiménez-Xarrié E, Davila M, Candiota AP, Delgado-Mederos R, Ortega-Martorell S, Julià-Sapé M, Arús C, Martí-Fàbregas J.

BMC Neurosci. 2017 Jan 13;18(1):13. doi: 10.1186/s12868-016-0328-x.

7.

Development of a transplantable glioma tumour model from genetically engineered mice: MRI/MRS/MRSI characterisation.

Ciezka M, Acosta M, Herranz C, Canals JM, Pumarola M, Candiota AP, Arús C.

J Neurooncol. 2016 Aug;129(1):67-76. doi: 10.1007/s11060-016-2164-3. Epub 2016 Jun 21.

PMID:
27324642
8.

MRSI-based molecular imaging of therapy response to temozolomide in preclinical glioblastoma using source analysis.

Delgado-Goñi T, Ortega-Martorell S, Ciezka M, Olier I, Candiota AP, Julià-Sapé M, Fernández F, Pumarola M, Lisboa PJ, Arús C.

NMR Biomed. 2016 Jun;29(6):732-43. doi: 10.1002/nbm.3521. Epub 2016 Apr 8.

PMID:
27061401
9.

Classification of brain tumours from MR spectra: the INTERPRET collaboration and its outcomes.

Julià-Sapé M, Griffiths JR, Tate RA, Howe FA, Acosta D, Postma G, Underwood J, Majós C, Arús C.

NMR Biomed. 2016 Mar;29(3):371. doi: 10.1002/nbm.3483. Epub 2015 Dec 22. No abstract available.

PMID:
26915795
10.

Improving Ribosomal RNA Integrity in Surgically Resected Human Brain Tumor Biopsies.

Castells Domingo X, Ferrer-Font L, Davila M, Candiota AP, Simões RV, Fernández-Coello A, Gabarrós A, Boluda S, Barceló A, Ariño J, Arús C.

Biopreserv Biobank. 2016 Apr;14(2):156-64. doi: 10.1089/bio.2015.0086. Epub 2016 Feb 17.

PMID:
26886080
11.

Classification of brain tumours from MR spectra: the INTERPRET collaboration and its outcomes.

Julià-Sapé M, Griffiths JR, Tate AR, Howe FA, Acosta D, Postma G, Underwood J, Majós C, Arús C.

NMR Biomed. 2015 Dec;28(12):1772-87. doi: 10.1002/nbm.3439. Review. Erratum in: NMR Biomed. 2016 Mar;29(3):371. Tate, Rosemary A [Corrected to Tate, A Rosemary].

PMID:
26768492
12.

From raw data to data-analysis for magnetic resonance spectroscopy--the missing link: jMRUI2XML.

Mocioiu V, Ortega-Martorell S, Olier I, Jablonski M, Starcukova J, Lisboa P, Arús C, Julià-Sapé M.

BMC Bioinformatics. 2015 Nov 9;16:378. doi: 10.1186/s12859-015-0796-5.

13.

Protein Kinase CK2 Content in GL261 Mouse Glioblastoma.

Ferrer-Font L, Alcaraz E, Plana M, Candiota AP, Itarte E, Arús C.

Pathol Oncol Res. 2016 Jul;22(3):633-7. doi: 10.1007/s12253-015-9987-7. Epub 2015 Oct 14.

PMID:
26466942
14.

In vivo and ex vivo magnetic resonance spectroscopy of the infarct and the subventricular zone in experimental stroke.

Jiménez-Xarrié E, Davila M, Gil-Perotín S, Jurado-Rodríguez A, Candiota AP, Delgado-Mederos R, Lope-Piedrafita S, García-Verdugo JM, Arús C, Martí-Fàbregas J.

J Cereb Blood Flow Metab. 2015 May;35(5):828-34. doi: 10.1038/jcbfm.2014.257. Epub 2015 Jan 21.

15.

Robustness of equations that define molecular subtypes of glioblastoma tumors based on five transcripts measured by RT-PCR.

Castells X, Acebes JJ, Majós C, Boluda S, Julià-Sapé M, Candiota AP, Ariño J, Barceló A, Arús C.

OMICS. 2015 Jan;19(1):41-51. doi: 10.1089/omi.2014.0077.

16.

Molecular imaging coupled to pattern recognition distinguishes response to temozolomide in preclinical glioblastoma.

Delgado-Goñi T, Julià-Sapé M, Candiota AP, Pumarola M, Arús C.

NMR Biomed. 2014 Nov;27(11):1333-45. doi: 10.1002/nbm.3194. Epub 2014 Sep 10.

PMID:
25208348
17.

Multicentre evaluation of the INTERPRET decision support system 2.0 for brain tumour classification.

Julià-Sapé M, Majós C, Camins À, Samitier A, Baquero M, Serrallonga M, Doménech S, Grivé E, Howe FA, Opstad K, Calvar J, Aguilera C, Arús C.

NMR Biomed. 2014 Sep;27(9):1009-18. doi: 10.1002/nbm.3144. Epub 2014 Jul 18.

PMID:
25042391
18.

(1)H-MRS is useful to reinforce the suspicion of primary central nervous system lymphoma prior to surgery.

Mora P, Majós C, Castañer S, Sánchez JJ, Gabarrós A, Muntané A, Aguilera C, Arús C.

Eur Radiol. 2014 Nov;24(11):2895-905. doi: 10.1007/s00330-014-3308-5. Epub 2014 Jul 17.

PMID:
25027839
19.

Effect of acute hyperglycemia on moderately hypothermic GL261 mouse glioma monitored by T1-weighted DCE MRI.

Simões RV, Ortuño JE, Bokacheva L, Candiota AP, Ledesma-Carbayo MJ, Delgado-Goñi T, García-Martín ML, Santos A, Arús C.

MAGMA. 2015 Apr;28(2):119-26. doi: 10.1007/s10334-014-0447-2. Epub 2014 Jun 11.

PMID:
24916487
20.

A new ex vivo method to evaluate the performance of candidate MRI contrast agents: a proof-of-concept study.

Candiota AP, Acosta M, Simões RV, Delgado-Goñi T, Lope-Piedrafita S, Irure A, Marradi M, Bomati-Miguel O, Miguel-Sancho N, Abasolo I, Schwartz S Jr, Santamaria J, Penadés S, Arús C.

J Nanobiotechnology. 2014 Apr 5;12:12. doi: 10.1186/1477-3155-12-12.

Supplemental Content

Support Center